CytoDyn discloses unregistered equity sales raising ~$3.5M with heavy dilution

CytoDyn Inc.

Converted $2.0M of convertible note principal into ~9.8M shares via exchange; relied on Section 3(a)(9).
April 2023 private placement sold ~0.5M units at $0.23/unit; net proceeds ~$0.1M.
Mid-2023 offering raised ~$1.1M from 5.4M units at ~$0.20/unit; placement agent gets 12% fee plus warrants.
$2.3M placement agent notes converted into ~11.5M shares at $0.20/unit; additional ~11.5M warrants issued at $0.306/share.
Aggregate dilution from these transactions exceeds ~22M shares plus warrants; registration of resale shares committed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.